Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18793780 | GeneCull: Enabling High-Quality Gene Sequence Modeling via Evolution-Guided Data Pruning Criteria | August 2024 | September 2025 | Abandon | 14 | 1 | 1 | Yes | No |
| 18388798 | PERSONAL WELLNESS RECOMMENDATION ENGINE | November 2023 | December 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18372402 | METHODS AND SYSTEMS FOR ANNOTATING GENOMIC DATA | September 2023 | February 2025 | Abandon | 17 | 2 | 0 | Yes | No |
| 18465093 | METHODS OF CLASSIFYING AND TREATING PATIENTS | September 2023 | February 2025 | Abandon | 18 | 2 | 0 | Yes | No |
| 18237358 | MACHINE LEARNING SYSTEM FOR GENOTYPING PCR ASSAYS | August 2023 | November 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18230385 | NUCLEIC ACID-BASED DATA STORAGE | August 2023 | January 2026 | Abandon | 29 | 2 | 0 | No | No |
| 18230383 | NUCLEIC ACID-BASED DATA STORAGE | August 2023 | December 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18230382 | NUCLEIC ACID-BASED DATA STORAGE | August 2023 | October 2025 | Abandon | 26 | 2 | 0 | Yes | No |
| 17631269 | METHOD FOR ANALYSING LOSS-OF-HETEROZYGOSITY (LOH) FOLLOWING DETERMINISTIC RESTRICTION-SITE WHOLE GENOME AMPLIFICATION (DRS-WGA). | January 2022 | March 2026 | Allow | 49 | 1 | 0 | Yes | No |
| 17343305 | SYSTEM AND METHOD FOR MOLECULAR DYNAMICS ANALYSIS | June 2021 | May 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17328765 | NANO COMPUTING DEVICE AND METHOD OF OPERATING NANO COMPUTING DEVICE | May 2021 | February 2026 | Allow | 56 | 2 | 1 | Yes | No |
| 17211003 | TAU PROTEIN ACCUMULATION PREDICTION APPARATUS USING MACHINE LEARNING AND TAU PROTEIN ACCUMULATION PREDICTION METHOD USING THE SAME | March 2021 | May 2025 | Abandon | 50 | 4 | 0 | No | No |
| 17272517 | METHOD FOR ASSESSING GENOME ALIGNMENT BASIS | March 2021 | January 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17271652 | SELF-LEARNING INPUT FILTER FOR MEDICAL DEVICES | February 2021 | November 2025 | Allow | 57 | 3 | 0 | Yes | No |
| 17271286 | Biological Information Analysis Device, Biological Information Analysis Method, and Biological Information Analysis System | February 2021 | November 2025 | Abandon | 56 | 2 | 0 | No | No |
| 17266689 | DETERMINING PROTEIN DISTANCE MAPS BY COMBINING DISTANCE MAPS CROPS | February 2021 | March 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17266115 | FREE ENERGY PERTURBATION COMPUTATION SCHEDULING METHOD USED IN HETEROGENEOUS CLUSTER ENVIRONMENT | February 2021 | October 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17265708 | MACHINE LEARNING FOR DETERMINING PROTEIN STRUCTURES | February 2021 | March 2025 | Abandon | 49 | 3 | 0 | Yes | Yes |
| 17140253 | Quantum Computing System | January 2021 | June 2025 | Abandon | 53 | 2 | 0 | No | No |
| 17257545 | METHOD FOR MEASURING CONCENTRATION OF BIOMETRIC MEASUREMENT OBJECT BY USING ARTIFICIAL INTELLIGENCE DEEP LEARNING | December 2020 | July 2025 | Abandon | 54 | 2 | 0 | No | No |
| 17255722 | METHODS AND COMPOSITIONS FOR IMPROVED MULTIPLEX GENOTYPING AND SEQUENCING | December 2020 | December 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 17118421 | ENHANCED PROTEIN STRUCTURE PREDICTION USING PROTEIN HOMOLOG DISCOVERY AND CONSTRAINED DISTOGRAMS | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17110953 | SOFT TISSUE MATERIAL CUMULATIVE DAMAGE MODEL FOR REDUCING REPETITIVE STRESS INJURIES IN PERFORMING A PROCESS | December 2020 | November 2025 | Allow | 59 | 5 | 0 | Yes | No |
| 17053054 | METHOD, APPARATUS, AND SYSTEM FOR DETECTING CHROMOSOME ANEUPLOIDY | November 2020 | March 2026 | Abandon | 60 | 4 | 0 | Yes | No |
| 17024656 | METHOD FOR BUILDING PREDICTIVE MODEL OF MICROORGANISM-DERIVED DISSOLVED ORGANIC NITROGEN IN WASTEWATER | September 2020 | February 2025 | Abandon | 53 | 2 | 0 | No | No |
| 16945642 | SYSTEMS, DEVICES, AND METHODS FOR GENERATING MACHINE LEARNING MODELS AND USING THE MACHINE LEARNING MODELS FOR EARLY PREDICTION AND PREVENTION OF PREECLAMPSIA | July 2020 | July 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16942222 | KINEMATIC MODELING OF BIOCHEMICAL PATHWAYS | July 2020 | April 2025 | Abandon | 56 | 2 | 0 | Yes | No |
| 16940380 | NORMALIZING CHROMOSOMES FOR THE DETERMINATION AND VERIFICATION OF COMMON AND RARE CHROMOSOMAL ANEUPLOIDIES | July 2020 | March 2025 | Allow | 56 | 2 | 0 | Yes | No |
| 16920514 | METHOD AND SYSTEM FOR PERSONALIZED, MOLECULAR BASED HEALTH MANAGEMENT AND DIGITAL CONSULTATION AND TREATMENT | July 2020 | December 2024 | Abandon | 53 | 2 | 1 | Yes | No |
| 16847064 | NUCLEIC ACID-BASED DATA STORAGE | April 2020 | March 2026 | Abandon | 60 | 3 | 0 | Yes | No |
| 16755233 | METHOD AND SYSTEM FOR CHARACTERIZATION OF METABOLISM-ASSOCIATED CONDITIONS, INCLUDING DIAGNOSTICS AND THERAPIES, BASED ON BIOINFORMATICS APPROACH | April 2020 | October 2024 | Abandon | 54 | 2 | 0 | No | No |
| 16638081 | METHOD FOR DETECTING GENE REARRANGEMENT BY USING NEXT GENERATION SEQUENCING | February 2020 | March 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16626200 | METHOD FOR DETERMINING THE RISK TO DEVELOP TYPE 1 DIABETES | December 2019 | January 2026 | Allow | 60 | 4 | 0 | No | No |
| 16614588 | METHOD FOR MEASURING ALPHA VALUE OF MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | November 2019 | January 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16669103 | NONINVASIVE PRENATAL DIAGNOSIS OF FETAL TRISOMY BY ALLELIC RATIO ANALYSIS USING TARGETED MASSIVELY PARALLEL SEQUENCING | October 2019 | March 2025 | Abandon | 60 | 3 | 0 | Yes | No |
| 16552653 | ANALYSIS METHOD, INFORMATION PROCESSING APPARATUS, GENE ANALYSIS SYSTEM AND NON-TRANSITORY STORAGE MEDIUM | August 2019 | January 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16504184 | SYSTEM AND METHOD FOR PREDICTING EFFECT OF GENOMIC VARIATIONS ON PRE-MRNA SPLICING | July 2019 | October 2024 | Abandon | 60 | 4 | 0 | Yes | No |
| 16459948 | DETERMINING CELL, TISSUE, OR LESION REPRESENTATIONS IN CELL-FREE DNA | July 2019 | May 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16446143 | METHODS, APPARATUSES, AND SYSTEMS FOR ANALYZING MICROORGANISM STRAINS IN COMPLEX HETEROGENEOUS COMMUNITIES, DETERMINING FUNCTIONAL RELATIONSHIPS AND INTERACTIONS THEREOF, AND DIAGNOSTICS AND BIOSTATE MANAGEMENT AND BIOSTATE TEMPORAL FORECASTING BASED THEREON | June 2019 | November 2024 | Abandon | 60 | 1 | 1 | No | No |
| 15601282 | INSULIN DELIVERY SYSTEM AND METHODS WITH RISK-BASED SET POINTS | May 2017 | January 2025 | Allow | 60 | 5 | 0 | No | No |
| 13869857 | Methods and Systems for Identification of a Protein Binding Site | April 2013 | July 2025 | Abandon | 60 | 10 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VASSELL, MEREDITH ABBOTT.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VASSELL, MEREDITH ABBOTT works in Art Unit 1687 and has examined 32 patent applications in our dataset. With an allowance rate of 31.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 57 months.
Examiner VASSELL, MEREDITH ABBOTT's allowance rate of 31.2% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VASSELL, MEREDITH ABBOTT receive 2.91 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by VASSELL, MEREDITH ABBOTT is 57 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +37.5% benefit to allowance rate for applications examined by VASSELL, MEREDITH ABBOTT. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.0% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 14.3% of cases where such amendments are filed. This entry rate is in the 15% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 84% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.